IOL Chemicals and Pharmaceuticals reports Q3 FY25 revenue at Rs. 527.37 Cr

Total Income during Q3 FY25 stood at Rs. 527.37 crore as compared to Rs. 528.77 crore in Q3 FY24

Utthunga partners with VindAir to advance smart solutions for pharma industry

The company will offer end-to-end services and solutions for the sector with a specific focus on sustainability

Cosmo and Glenmark receives UK MHRA approval to market Winlevi in UK

NURA AI Health Screening Centre Bengaluru celebrates 4th anniversary of transforming lives through early detection

Plans underway to expand screening capacity by 50% for greater accessibility

P. D. Hinduja Hospital spreads solidarity for cancer awareness

Cancer cases in India estimated to reach 1.57 million in 2025

Tata Chemicals signs MoU with BSDT’s Integrated Cancer Treatment and Research Centre, Pune

This collaboration aims to bridge modern scientific research with traditional Ayurvedic wisdom, fostering innovative solutions that support holistic well-being

Hikal Q3 FY25 consolidated revenue recorded at Rs. 448 Cr

The stable raw materials prices, focused cost improvement initiatives and intensified customer acquisitions helped the company to improve its margin profile

JB Pharma reports revenue growth of 14% in Q3 FY25; Net profit up by 22%

Profit after Taxes registered strong growth of 22% to Rs. 162 crores versus Rs. 134 crores in Q3 FY24

Akums combines two potent diabetes medicines for enhanced treatment efficacy

Akums Drugs & Pharmaceuticals has launched Dapagliflozin + Pioglitazone tablets, a dual-action therapy for diabetes management

Gland Pharma reports Q3 FY25 revenue at Rs. 1,384 Cr

Our Q3 FY25 revenue was at Rs. 1,384.1 crore with an EBITDA of Rs. 360 crore resulting in a 26% EBITDA margin